NON INVASIVE PRENATAL DIAGNOSTICS
NON-INVASIVE PRENATAL DIAGNOSTICS – VERIFI PRENATAL TEST
A little-known fact is that fetal DNA circulates in the blood of the pregnant mother. The principle of non-invasive prenatal diagnostics (NIPT) is formulated on the basis of this fact, allowing the screening of fetal DNA in a mother’s blood sample. The prenatal test Verifi is available in our laboratory used for screening for certain genetic conditions as early as week 10 of pregnancy. Using the latest genetic sequencing technology, these tests have over >99 accuracy for dwtecting a plethora of genetic conditions such as trisomies, aneuploidies, deletion/duplication syndromes and gender identification.
The test imposes no risk to the health of the mother or the health of the baby, as it minimizes the dangers posed by other prenatal tests that induce invasive procedures such as amniocentesis or chorionic villus sampling.
What is necessary is only 10 ml of blood taken from the mother.
Available Verifi tests in our laboratory:
- Verifi (chromosomes 13, 18, 21, X, Y)
- Verifi del (with microdeletions)
- Verifi Plus (all chromosomes)
- Verifi del Plus (all chromosomes and microdeletions)
The prenatal test verifi applies a deeper scientific approach, more advanced and modern technology than other prenatal tests – it is performed with next generation sequencing (NGS). It is a test that detects all chromosomal aberrations which can affect the health and the development of the baby – it detects an increased or decreased number of whole chromosomes, and also the absence of larger regions on the chromosomes.
Chromosomes that are missing or are additionally present are called aneuploidies, and the absences of larger chromosomal regions are called microdeletions. Both forms of chromosomal aberrations are associated with a manifestation of psychological or physical disabilities with varying degrees of severity.
With the verifi test, all possible aneuploidies can be detected on all human chromosomes (such as Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, Klinefelter syndrome, Triple X syndrome, etc.), and the following microdeletions syndromes are included: deletion 22q11.2 ( DiGeorge syndrome), deletion 1p36, microdeletion 15q11.2 (Angelman syndrome), microdeletion 15q11.2 (Prader-Willi syndrome), 5p-syndrome (Cri du chat syndrome) 4p-syndrome (Wolf-Hirschhorn syndrome).
The results are clear and unambiguous, ie they can be positive or negative.
- Simple, safe – does not include amniocentesis or chorionic villus sampling – just a blood draw from the mother
- Timely – can be done starting from the 10 week of pregnancy
- Precise – provides reliable results for chromosomal and sub-chromosomal abnormalities
- Allows screening of abnormalities in sex chromosomes in single pregnancies
- Provides the determination of the sex of the baby both in single and twin pregnancies
- Allows detection of additional abnormalities, i.e. detection of microdeletions
- Has the lowest degree of failure among all tests of this type
- Provides fast results – results are reported within 5-7 working days after taking the sample
- Advanced maternal age (35 years or more for a single pregnancy and 32 or more for a twin pregnancy)
- Prenatal screening that is either positive or abnormal
- Detected abnormalities in fetal growth and/or development via ultrasound
- Positive personal/family history